PR No. 75 PHARMACOVIGILANCE CENTRE, NATIONAL PHARMACOVIGILANCE COMMISSION AND ADVISORY COMMITTEE TO BE SET UP IN DRAP Islamabad: May 11, 2018

A meeting was held between Chief Executive Officer, DRAP and United States Pharmacopoeia experts, namely Dr. Souly Phanovong and Dr. Rachida Soulaymanion 09.05.2018 in the DRAP office to discuss a roadmap for establishment of Pharmacovigilance (PV) Centre in the DRAP. After deliberation with the international experts, it was resolved that fully functional PV Centre shall be set up at the federal level in DRAP with regional PV center at provincial levels. In the first phase Tertiary Care private hospitals shall also be part of the activity for reporting adverse events/effects. It was also resolved that a National PV Commission and an Advisory Committee to oversee / supervise the PV activity shall be formed and concerted effort shall be made as early as possible for the approval of PV Rules, 2018 by Federal Government to provide the legal cover. Dr. Souly and Dr. RachidaSoulaymani appreciated the online reporting forms developed by DRAP and formally inaugurated launching of online reporting form namely Med Vigilance on DRAP’s official website, which gives option for patients, Health Care Professionals and Pharma companies to report the adverse effects / events. In closing remarks, CEO, DRAP thanked the international experts for sharing their knowledge and experience with the participants with regards to PV concepts, methods and tools. He also requested Dr. RachidaSoulaymani to develop the PV strategy for DRAP center for coming 2-3 years so that signals be detected the earliest stages and appropriate risk minimization measures be taken for the patients safety. DRAP would make a registration application for PV Centre for attaining full membership of WHO PV Centre at Uppsala, Sweden at an appropriate time.

PREVIOUS NEXT